Geun-Hyoung Ha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Geun-Hyoung Ha has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Kyeung Min Joo
Department of Anatomy & Cell Biology, Sungkyunkwan University School of Medicine, Suwon, South Korea
15 shared publications - Chung Kwon Kim
Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Suwon 16419, Korea
14 shared publications - Dong Geun Hong
Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul, Korea (South), Republic of
14 shared publications - Dong Oh Kim
Sungkyunkwan University School of Medicine, Suwon, Korea (South), Republic of
14 shared publications - Eun Hwa Jang
Sungkyunkwan University School of Medicine, Suwon, Korea (South), Republic of
14 shared publications - Hyun Nam
Medical Innovation Technology Inc. (MEDINNO Inc.), Seoul, Korea (South), Republic of
14 shared publications
Latest Publications
- Open Access
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
Therapeutic efficacy of CES1 and sTRAIL mRNAs delivered via WJ-MSCs in a lung cancer brain metastasis model. A, Schematic overview of the in vivo experimental design. B, Western blot analysis of CES1 and FLT-3L expression in WJ-MSCs transfected with LNP-encapsulated mRNAs. C, Bioluminescence imaging of tumor-bearing mice performed using the IVIS imaging system. D, Quantification of bioluminescent signals at 14 days after H460-Luc cell injection. NS, not significant. E, Body weight monitoring of nude mice throughout the treatment period. Data are presented as the mean ± SD; n = 5 per group. P values of statistical significance are represented as *, P < 0.05; **, P < 0.001.
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
Therapeutic efficacy of CES1 and sTRAIL mRNAs delivered via WJ-MSCs in a lung cancer brain metastasis model. A, Schematic overview of the in vivo experimental design. B, Western blot analysis of CES1 and FLT-3L expression in WJ-MSCs transfected with LNP-encapsulated mRNAs. C, Bioluminescence imaging of tumor-bearing mice performed using the IVIS imaging system. D, Quantification of bioluminescent signals at 14 days after H460-Luc cell injection. NS, not significant. E, Body weight monitoring of nude mice throughout the treatment period. Data are presented as the mean ± SD; n = 5 per group. P values of statistical significance are represented as *, P < 0.05; **, P < 0.001.
- Open Access
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
We aimed to develop a novel therapeutic strategy for lung cancer brain metastases by leveraging the tumor-tropic properties of genetically engineered Wharton’s Jelly–derived mesenchymal stem cells (WJ-MSC) as vehicles for dual-agent gene therapy across the blood–brain barrier. WJ-MSCs were transiently engineered using lipid nanoparticle technology to coexpress soluble TRAIL (sTRAIL) and the prodrug-activating enzyme carboxylesterase 1 (CES1). In vitro analyses assessed transfection efficiency, therapeutic protein expression, apoptosis induction, and maintenance of stemness. Tumor-homing capacity was evaluated via EGFP labeling and intracerebral tracking. Therapeutic efficacy was tested in subcutaneous and intracerebral lung cancer xenograft models using bioluminescent imaging, histopathology, and IHC. In vivo treatment included intraperitoneal CPT-11 administration to assess synergy between CES1-mediated prodrug activation and sTRAIL-induced apoptosis. Modified WJ-MSCs exhibited preserved stem cell characteristics and strong tropism toward brain tumor sites. They secreted high levels of functional sTRAIL and CES1, enabling local activation of CPT-11 into SN-38 and inducing apoptosis through death receptor signaling (DR4/DR5). Combination therapy with WJ-MSCs-CES1.sTRAIL and CPT-11 significantly suppressed tumor growth in lung cancer brain metastasis models compared with control groups. The approach demonstrated selective cytotoxicity, minimal off-target effects, and favorable safety profiles. This study establishes a nonviral, transient gene delivery platform using autologous WJ-MSCs for dual-action gene therapy in lung cancer brain metastases. The combined use of CES1 and sTRAIL and enables precise tumor targeting and drug activation, offering a promising avenue for personalized, stem cell–based treatment strategies to improve outcomes in patients with brain metastatic lung cancer.Significance:This study presents a nonviral, stem cell–based therapy for brain metastatic non–small cell lung cancer using WJ-MSCs expressing sTRAIL and CES1. These engineered cells home to tumors, activate CPT-11, and induce apoptosis. The dual-action strategy significantly reduced brain tumor burden with minimal toxicity, demonstrating strong therapeutic potential.
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
We aimed to develop a novel therapeutic strategy for lung cancer brain metastases by leveraging the tumor-tropic properties of genetically engineered Wharton’s Jelly–derived mesenchymal stem cells (WJ-MSC) as vehicles for dual-agent gene therapy across the blood–brain barrier. WJ-MSCs were transiently engineered using lipid nanoparticle technology to coexpress soluble TRAIL (sTRAIL) and the prodrug-activating enzyme carboxylesterase 1 (CES1). In vitro analyses assessed transfection efficiency, therapeutic protein expression, apoptosis induction, and maintenance of stemness. Tumor-homing capacity was evaluated via EGFP labeling and intracerebral tracking. Therapeutic efficacy was tested in subcutaneous and intracerebral lung cancer xenograft models using bioluminescent imaging, histopathology, and IHC. In vivo treatment included intraperitoneal CPT-11 administration to assess synergy between CES1-mediated prodrug activation and sTRAIL-induced apoptosis. Modified WJ-MSCs exhibited preserved stem cell characteristics and strong tropism toward brain tumor sites. They secreted high levels of functional sTRAIL and CES1, enabling local activation of CPT-11 into SN-38 and inducing apoptosis through death receptor signaling (DR4/DR5). Combination therapy with WJ-MSCs-CES1.sTRAIL and CPT-11 significantly suppressed tumor growth in lung cancer brain metastasis models compared with control groups. The approach demonstrated selective cytotoxicity, minimal off-target effects, and favorable safety profiles. This study establishes a nonviral, transient gene delivery platform using autologous WJ-MSCs for dual-action gene therapy in lung cancer brain metastases. The combined use of CES1 and sTRAIL and enables precise tumor targeting and drug activation, offering a promising avenue for personalized, stem cell–based treatment strategies to improve outcomes in patients with brain metastatic lung cancer.Significance:This study presents a nonviral, stem cell–based therapy for brain metastatic non–small cell lung cancer using WJ-MSCs expressing sTRAIL and CES1. These engineered cells home to tumors, activate CPT-11, and induce apoptosis. The dual-action strategy significantly reduced brain tumor burden with minimal toxicity, demonstrating strong therapeutic potential.
- Open Access
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
Therapeutic tumor-homing ability of MSCs. A, Schematic representation of an in vivo experiment. B, Confirming EGFP expression in Western blot results of WJ-MSCs transfected with LNP-mRNA. C, The CLSM results depict brain cross-sections from 0 to 48 hours after ICV injection of WJ-MSCs-mRNA-EGFP into mouse brains. (Green represents Alexa Fluor 488 fluorescence, and blue represents DAPI staining). CLSM, confocal laser scanning microscope; DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride.
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
Therapeutic tumor-homing ability of MSCs. A, Schematic representation of an in vivo experiment. B, Confirming EGFP expression in Western blot results of WJ-MSCs transfected with LNP-mRNA. C, The CLSM results depict brain cross-sections from 0 to 48 hours after ICV injection of WJ-MSCs-mRNA-EGFP into mouse brains. (Green represents Alexa Fluor 488 fluorescence, and blue represents DAPI staining). CLSM, confocal laser scanning microscope; DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride.
- Open Access
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
Therapeutic effects of treatment genes on lung cancer brain metastasis in vivo. A, Confirming CES1 and FLT-3L expression in Western blot results of H460-Luc cells transfected with LNP-mRNA. B, Bioluminescence imaging was conducted using IVIS Optical Imaging equipment during the experiment. The bioluminescent image of the first mouse in the mock day 7 condition is also presented for the day 7 condition in Fig. 3A, as the images represent the same experimental conditions. C, Bioluminescent signals were quantified using the IVIS imaging system, and results were obtained at 7 and 14 days after injecting H460-Luc cells for each group. D, Mouse body weight changes after injecting H460-Luc cells with transfection were assessed in each group of nude mice. E, Histologic analysis of tumor tissues in the H460-Luc model, stained with hematoxylin and eosin (H&E), Ki67, and cleaved caspase-3. F, A graph illustrating the area of cancer lesions in the mouse brain. All results are expressed as the mean ± SD; N = 5 for all groups. P values of statistical significance are represented as *, P < 0.05; **, P < 0.001; and ***, P < 0.0001.
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
Therapeutic effects of treatment genes on lung cancer brain metastasis in vivo. A, Confirming CES1 and FLT-3L expression in Western blot results of H460-Luc cells transfected with LNP-mRNA. B, Bioluminescence imaging was conducted using IVIS Optical Imaging equipment during the experiment. The bioluminescent image of the first mouse in the mock day 7 condition is also presented for the day 7 condition in Fig. 3A, as the images represent the same experimental conditions. C, Bioluminescent signals were quantified using the IVIS imaging system, and results were obtained at 7 and 14 days after injecting H460-Luc cells for each group. D, Mouse body weight changes after injecting H460-Luc cells with transfection were assessed in each group of nude mice. E, Histologic analysis of tumor tissues in the H460-Luc model, stained with hematoxylin and eosin (H&E), Ki67, and cleaved caspase-3. F, A graph illustrating the area of cancer lesions in the mouse brain. All results are expressed as the mean ± SD; N = 5 for all groups. P values of statistical significance are represented as *, P < 0.05; **, P < 0.001; and ***, P < 0.0001.
- Open Access
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
In vivo of therapeutic efficacy of LNP-mRNA-MSCs for H460-Luc. A, Schematic representation of an in vivo experiment. B, Confirming CES1 and FLT-3L expression in Western blot results of WJ-MSCs transfected with LNP-mRNA. C, A graph shows changes in the body weight of nude mice during WJ-MSCs-mRNA treatment. D, Average tumor volume. E, Average tumor weight. NS, not significant. F, Representative subcutaneous tumors in the control and treatment groups. All results are expressed as the mean ± SD; N = 6 for all groups. P values of statistical significance are represented as *, P < 0.05; **, P < 0.001; and ***, P < 0.0001.
- 9 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Mesenchymal Stem Cells Expressing CES1 and Soluble TRAIL Activate CPT-11 and Induce Apoptosis in Lung Cancer Brain Metastatic Lesions
In vivo of therapeutic efficacy of LNP-mRNA-MSCs for H460-Luc. A, Schematic representation of an in vivo experiment. B, Confirming CES1 and FLT-3L expression in Western blot results of WJ-MSCs transfected with LNP-mRNA. C, A graph shows changes in the body weight of nude mice during WJ-MSCs-mRNA treatment. D, Average tumor volume. E, Average tumor weight. NS, not significant. F, Representative subcutaneous tumors in the control and treatment groups. All results are expressed as the mean ± SD; N = 6 for all groups. P values of statistical significance are represented as *, P < 0.05; **, P < 0.001; and ***, P < 0.0001.